IFN-β therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses
IFN-β corrects low serum type I IFN levels, enhances responses to subsequent IFN exposure, induces immunoregulatory and neuroprotective proteins, and balances dysregulated and subnormal serum cytokine levels. Low serum IFN and IFN-β-induced proteins link to better long-term response to IFN-β therapy. Correction of immune disruption suggests new mechanisms for immunopathology and therapy.
Authors
- Maya Olcer (ORCID: https://orcid.org/0000-0003-4945-089X)
- Jin Ke (ORCID: https://orcid.org/0000-0001-8887-3743)
- Anthony T. Reder (ORCID: https://orcid.org/0000-0002-6423-1495)
- Zhe Wang (ORCID: https://orcid.org/0000-0001-9117-7917)
- Lei Li (ORCID: https://orcid.org/0000-0001-9910-5600)
- Xuan Feng (ORCID: https://orcid.org/0000-0003-1661-6590)
- Yaerin Song (ORCID: https://orcid.org/0000-0002-9111-8519)
Institutions
- Harbin Medical University (CN)
- Dalian Medical University (CN)
- University of Illinois Chicago (US)
- University of Chicago (US)
- Second Affiliated Hospital of Dalian Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1371/journal.pone.0330867
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00